Humacyte: Creating New Medical Frontiers With Bioengineered Human Tissue

(26min)

Summary

  • Humacyte, a bioengineering company, went public through a SPAC merger in 2015, with a market value of $1.1 billion.
  • The company has received FDA's RMAT designation for three indications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease.
  • Humacyte's potential product, Acellular Tissue Engineered Vessel, has shown promise in addressing critical medical needs, with a pending FDA approval decision on August 10th.

Female surgeon operating patient at emergency room

Morsa Images

Twenty years ago, Drs. Laura Niklason, Juliana Blum, and Shannon Dahl saw the need to develop a method for creating human tissue to address many medical conditions that impact our human body. With this vision for a future medical solution in mind, these three

This article was written by

I'm retired from a near 40 year career in the publishing industry working with an international publishing company. I obtained the position of Vice President and I led the sales efforts in the two largest markets in the textbook industry -California and Texas. My investing experience is over a span of 40 years.Luckily with more winners than losers! My hobbies are traveling , reading good books(non-fiction)--and researching stocks that I have an interest. I teach a continuing education class at our local college each semester. I volunteer my time working in assisting several lawyers with their Child Protective Service cases.Drugs are destroying our society and family structure). Finally, I serve as a reviewer for a national literary prize given each year. No pay, but I get to keep the books and add to my ever growing library. Other than these activities---I'm just plain lazy!

Analyst’s Disclosure: I/we have a beneficial long position in the shares of HUMA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About HUMA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on HUMA

Related Stocks

SymbolLast Price% Chg
HUMA
--
HUMAW
--